Draper took to X, sharing his recent interview on the Founders Room Podcast, in which he talked about the increasing dominance of Bitcoin in the blockchain space. “I think there’s a gravitational pull ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

Parth is a technology analyst and writer specializing in the comprehensive review and feature exploration of the Android ecosystem. His work is distinguished by its meticulous focus on flagship ...

Investing.com -- Replimune Group Inc (NASDAQ:REPL) stock tumbled 36% premarket after STAT reported that the FDA’s top cancer drug regulator intervened late in the review process of the company’s skin ...

Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

Investing.com -- Replimune Group, Inc. (NASDAQ:REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

Somewhere in the blur of 2020, as I slipped outside with a mask and running shoes in the early morning to walk around the block, the lilting drawl of a friend’s “hiiiiii” nearly stopped me in my ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline candidate, RP1 (vusolimogene oderparepvec), in combination with Bristol ...